China Resources Double-Crane Pharmaceutical (SHA:600062) said its pentazocine injection passed the generic drug quality and efficacy consistency evaluation.
The notice was issued by the National Medical Products Administration, according to a Dec. 31 filing with the Shanghai bourse.
Pentazocine is used to treat severe chronic pain and serves as a pre-anesthetic as an auxiliary drug for surgical anesthesia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。